|
End-of-day quote
Korea S.E.
20/08/2026
|
5-day change | 1st Jan Change | ||
| 5,820.00 KRW | +2.28% |
|
+3.19% | -14.66% |
| 09/12 | GC Genome Study Identifies 'Confounders' Interfering with Cancer Signals to Improve Liquid Biopsy Accuracy | CI |
| 12/25/12 | GC Genome Shares Decline Nearly 3% After Strong Kosdaq Debut | MT |
Business description: GC Genome Corporation

Executive Committee: GC Genome Corporation
| Manager | Title | Age | Since |
|---|---|---|---|
Chang-Seok Gi
CEO | Chief Executive Officer | 57 | 26/03/2020 |
Sang-Hun Jeong
DFI | Director of Finance/CFO | 50 | 27/03/2025 |
Seu-Nga Hyun
AUD | Comptroller/Controller/Auditor | 45 | 29/03/2024 |
Eun-Hae Jo
PRN | Corporate Officer/Principal | 52 | - |
Composition of the Board of Directors: GC Genome Corporation
| Director | Title | Age | Since |
|---|---|---|---|
Sang-Uk Kim
BRD | Director/Board Member | 57 | 30/03/2023 |
Company details: GC Genome Corporation

Medical & Diagnostic Laboratories
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
| +2.28% | +3.19% | -23.52% | - | 9.68Cr | ||
| -0.07% | +2.81% | +102.87% | +517.57% | 4.69TCr | ||
| +0.72% | +2.88% | +20.68% | +55.21% | 2.68TCr | ||
| -9.25% | -4.13% | -26.10% | -34.36% | 828.69Cr | ||
| +2.00% | +0.13% | +13.43% | +159.17% | 594.48Cr | ||
| +0.12% | -3.27% | +11.59% | +68.55% | 329.85Cr | ||
| +3.64% | +0.19% | -31.58% | +1,602.06% | 237.54Cr | ||
| -0.75% | +0.67% | +161.97% | +21.99% | 213.98Cr | ||
| +10.01% | +1.62% | +0.10% | -51.24% | 192.41Cr | ||
| -0.66% | -1.04% | +29.96% | +18.42% | 192.11Cr | ||
| Average | +0.79% | +0.69% | +25.94% | +261.93% | 996.43Cr | |
| Weighted average by Cap. | -0.31% | +2.10% | +56.23% | +305.47% |
Sector
Annual profits - Rate of surprise
- Stock Market
- Stocks
- A340450 Stock
- Company GC Genome Corporation
Select your edition
All financial news and data tailored to specific country editions

















